Molecular study of weight gain related to atypical antipsychotics: Clinical implications of the CYP2D6 genotype

Romanian Journal of Morphology and Embryology

Volumn 55, Issue 3, 2014, Pages 877-884

  Nussbaum, Laura Alexandra ^a   Dumitraşcu, Victor ^a   Tudor, Anca ^a   Grădinaru, Raluca ^a   Andreescu, Nicoleta ^a   Puiu, Maria ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Atypical antipsychotics; Child schizophrenia; CYP2D6 genotype; Pharmacogenetics; Weight gain

Indexed keywords

CYTOCHROME P450 2D6; INSULIN; NEUROLEPTIC AGENT;

ADOLESCENT; ALLELE; BIPOLAR DISORDER; BLOOD; BODY MASS; CHILD; DRUG EFFECTS; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; SCHIZOPHRENIA; TIME; WEIGHT GAIN; YOUNG ADULT;

ADOLESCENT; ALLELES; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BODY MASS INDEX; CHILD; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN; MALE; SCHIZOPHRENIA; TIME FACTORS; WEIGHT GAIN; YOUNG ADULT;

EID: 84908246564     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Müller DJ, Peter C, Puls I, Brandl EJ, Lang UE, Gallinat J, Heinz A, Genetik der Antipsychotika-assoziierten Gewichtszunahme, Nervenarzt, 2009, 80(5):556–563.
2. Wang PS, Wu SL, Ching HY, The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia, Int Clin Psychopharmacol, 2014, 29(4):235–238.
3. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC, Hebebrand J, Theisen FM, Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course, J Psychiatr Res, 2009, 43(6):620–626.
4. Gentile S, Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications, Obes Rev, 2009, 10(5): 527–542.
5. Allison DB, Loebel AD, Lombardo I, Romano SJ, Siu CO, Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean? Psychiatry Res, 2009, 170(2–3):172–176.
6. Newcomer JW, Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review, CNS Drugs, 2005, 19(Suppl 1):1–93.
7. van Winkel R, De Hert M, Wampers M, Van Eyck D, Hanssens L, Scheen A, Peuskens J, Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder, J Clin Psychiatry, 2008, 69(3):472–479.
8. De Hert M, Mittoux A, He Y, Peuskens J, Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone, Eur Arch Psychiatry Clin Neurosci, 2011, 261(4):231–239.
9. Nasrallah HA, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles, Mol Psychiatry, 2008, 13(1):27–35.
10. Kim SH, Nikolics L, Abbasi F, Lamendola C, Link J, Reaven GM, Lindley S, Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents, J Psychiatr Res, 2010, 44(8):493–498.
11. Fraguas D, Merchán-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, Cifuentes A, Giráldez M, Arango C, Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics, J Clin Psychiatry, 2008, 69(7):1166–1175.
12. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, Charles Schulz S, Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia, Schizophr Bull, 2008, 34(1):60–71.
13. Maayan L, Correll CU, Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents, J Child Adolesc Psychopharmacol, 2011, 21(6): 517–535.
14. Lett TAP, Wallace TJM, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ, Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications, Mol Psychiatry, 2012, 17(3):242–266.
15. Bondy B, Spellmann I, Pharmacogenetics of antipsychotics: useful for the clinician? Curr Opin Psychiatry, 2007, 20(2): 126–130.
16. Chagnon YC, Susceptibility genes for the side effect of antipsychotics on body weight and obesity, Curr Drug Targets, 2006, 7(12):1681–1695.
17. Correll CU, Lencz T, Malhotra AK, Antipsychotic drugs and obesity, Trends Mol Med, 2011, 17(2):97–107.
18. Mackenzie B, Souza RP, Likhodi O, Tiwari AK, Zai CC, Sturgess J, Müller DJ, Pharmacogenetics of antipsychotic treatment response and side effects, Therapy, 2010, 7(2): 191–198.
19. Zhang JP, Malhotra AK, Pharmacogenetics of antipsychotics: recent progress and methodological issues, Expert Opin Drug Metab Toxicol, 2013, 9(2):183–191.
20. Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G, Stelzig-Schoeler R, Stuppaeck C, Geretsegger C, Influence of age and gender on risperidone plasma concentrations, J Psychopharmacol, 2005, 19(4):395–401.
21. Koola MM, Tsapakis EM, Wright P, Smith S, Kerwin Rip RW, Nugent KL, Aitchison KJ, Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites? J Psychopharmacol, 2014, 28(7):665–670.
22. Sheffield LJ, Phillimore HE, Clinical use of pharmacogenomic tests in 2009, Clin Biochem Rev, 2009, 30(2):55–65.
23. Herbild L, Andersen SE, Werge T, Rasmussen HB, Jürgens G, Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharmacol Toxicol, 2013, 113(4):266–272.
24. Müller DJ, Chowdhury NI, Zai CC, The pharmacogenetics of antipsychotic-induced adverse events, Curr Opin Psychiatry, 2013, 26(2):144–150.
25. Drozda K, Müller DJ, Bishop JR, Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options, Pharmacotherapy, 2014, 34(2):166–184.
26. Müller DJ, Kekin I, Kao ACC, Brandl EJ, Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic, Int Rev Psychiatry, 2013, 25(5):554–571.
27. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA, Applications of CYP450 testing in the clinical setting, Mol Diagn Ther, 2013, 17(3):165–184.
28. Laika B, Leucht S, Heres S, Steimer W, Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J, 2009, 9(6):395–403.
29. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ, The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation, J Clin Psychiatry, 2005, 66(1):15–27.
30. Yagihashi T, Mizuno M, Chino B, Sato Y, Sakuma K, Takebayashi T, Takao T, Kosaki K, Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia, Hum Psychopharmacol, 2009, 24(4):301–308.
31. Müller DJ, Kennedy JL, Genetics of antipsychotic treatment emergent weight gain in schizophrenia, Pharmacogenomics, 2006, 7(6):863–887.
32. Aman MG, Vinks AA, Remmerie B, Mannaert E, Ramadan Y, Masty J, Lindsay RL, Malone K, Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders, Clin Ther, 2007, 29(7):1476–1486.
33. Calarge CA, Miller del D, Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents, J Child Adolesc Psychopharmacol, 2011, 21(2): 163–169.
34. Zhang JP, Malhotra AK, Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction, Expert Opin Drug Metab Toxicol, 2011, 7(1):9–37.
35. Adkins DE, Aberg K, McClay JL, Bukszár J, Zhao Z, Jia P, Stroup TS, Perkins D, McEvoy JP, Lieberman JA, Sullivan PF, van den Oord EJ, Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs, Mol Psychiatry, 2011, 16(3):321–332.
36. de Leon J, Pharmacogenomics: the promise of personalized medicine for CNS disorders, Neuropsychopharmacology, 2009, 34(1):159–172.
37. de Leon J, Diaz FJ, Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy, Schizophr Res, 2007, 96(1–3):185–197.
38. Malhotra AK, Zhang JP, Lencz T, Pharmacogenetics in psychiatry: translating research into clinical practice, Mol Psychiatry, 2012, 17(8):760–769.
39. Foussias G, Remington G, Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making, Can J Psychiatry, 2010, 55(3):117–125.
40. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL, Genomewide association for schizophrenia in the CATIE study: results of stage 1, Mol Psychiatry, 2008, 13(6):570–584.
41. Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH, First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents, J Can Acad Child Adolesc Psychiatry, 2010, 19(2):124–137.
42. Reeves GM, Keeton C, Correll CU, Johnson JL, Hamer RM, Sikich L, Hazzard L, Alderman C, Scheer A, Mabe M, Kapoor S, Sheridan E, Borner I, Bussell K, Pirmohamed S, Bethea TC, Chekuri R, Gottfried R, Reinblatt SP, Santana E, Riddle MA, Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods, Child Adolesc Psychiatry Ment Health, 2013, 7(1):31.
43. Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, Lieberman JA, The impact of obesity on health care costs among persons with schizophrenia, Gen Hosp Psychiatry, 2009, 31(1):1–7.
44. Mukundan A, Faulkner G, Cohn T, Remington G, Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems, Cochrane Database Syst Rev, 2010, 12:CD006629.
45. Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network, A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP), Am J Psychiatry, 2011, 168(9):947–956.